|Application deadline:||June 24th, 2013|
|Tuition fee:|| |
|Start date:||September 2013|
|Credits:|| 60 ECTS |
|Duration full-time:||12 months|
|Educational variant:||Part-time, Full-time|
|Part-time variant:||Weekday, Weekend|
|Student interaction:||Individual work/assignments (with online group discussions)|
|Teacher support:||Continuous support with feedback on request|
The Eu2P Master is an academic post-graduate diploma in pharmacovigilance and pharmacoepidemiology jointly delivered by Eu2P Academic Partners. This European diploma is awarded under the authority of each national Ministry of Higher Education or ad hoc authority. The Eu2P Master is both supported and recognised by Eu2P regulatory and industrial partners.
The Eu2P Master offers six high level curricula to meet specific professional needs in the following specializations:
As for year 1, the Master year 2 programme is half-composed of theoretical training (course modules) and practical training (research project).
Each theoretical or practical part must be successfully completed by the trainee to obtain the Eu2P Master in Pharmacovigilance and Pharmacoepidemiology.
This second year allows trainees to choose a specialisation track to fit current or future professional needs.
Track #1 Benefit assessment of medicines
To know the scientific principles underlying the decision making process of prescribing To know the methods used in epidemiological studies and in randomized clinical trials to assess the efficacy and effectiveness of medicines To be aware of the limitations of scientific evidence in the benefit assessment of medicines To discuss and analyse the need to solve therapeutic uncertainties through clinical research
Track #2 Medicines risk identification and quantification
To enhance knowledge about and make the trainees capable of identifying and quantifying risks of medicines and to interpret publications and study results
Track #3 Medicines benefit-risk assessment
To obtain overview/basic insight into benefit-risk assessment methods (including pharmacoeconomics), the process of decision making on medicines by different stakeholders To obtain detailed insight into benefit-risk assessment methods (including pharmacoeconomics), the process of decision making on medicines by different stakeholders To be able to apply benefit-risk assessment methods in daily practice
Track #4 Medicines and public health
To provide intermediate and advanced knowledge of the effects of medicines from a public health point of view To develop theoretical and practical knowledge of the quantitative analysis of medicines utilisation To develop theoretical and practical knowledge of the qualitative analysis of medicines utilisation To know how to study the health and economical impact of side effects of medicines for the community
Track #5 Medicines risk communication
To get a clear understanding of the stakes and stakeholders' involvement in medicines risk communication and their determinants To have an accurate view of the way medicines risk communication works in the real life "A la carte" Eu2P Master Pharmacovigilance and Pharmacoepidemiology To get a general knowledge in all Master specialisations. This track is composed of four modules of your choice among the Master specialisations.
This Master year 2 targets academic students and professionnals with a Master year 1 level or an equivalence(*) in Health or Life sciences.
(*): see SELECTION BOARD section down this page.
To be eligible, you must:
Eu2P enables grant application for Master students.
Attributions of grant is based on merit and reasearch interest grounds.
You are normally required to take an English Proficiency Test if you come from a non-English speaking country.
Most European Universities recognise the IELTS test.More information on IELTS
Please fill in this form in English.
The fields that are marked with a red star (*) are required.